Business
CSL ‘cautious’ on profit outlook even after vaccines boosted half-year results – Sydney Morning Herald
Australia’s local maker of AstraZeneca Oxford’s COVID-19 jabs beat market expectations as sales of its seasonal influenza vaccines soared in the face of COVID-19,…
The full-year result will be heavily skewed to the first half, he told analysts. The impacts of COVID, both positive and negative, add a pretty heavy layer of complexity and uncertainty to our earnings profile until we get through this pandemic.
CSL maintained its previous earnings guidance, predicting profits of between $2.17 and $2.27 billion for the 2021 financial year. Asked why the $131 billion biotech wasnt increasing its forecasts, Mr Perreault highlighted that because of the seasonal nature…
-
Noosa News21 hours agoSpilt Milk Is Back for 2025 After Sitting 2024 Out— and Here’s the Touring Music Festival’s Summer Dates
-
Noosa News21 hours agoMan charged over alleged hit-and-run death of cyclist in Bundaberg
-
Noosa News18 hours agoNow Open: Josh and Julie Niland’s Catseye Pool Club Is Your New Excuse for a Hamilton Island Getaway
-
Noosa News12 hours agoBreakthrough clinical trial could change the lives of thousands living with diabetes